ArticleDiscover oncology2026
Primary small cell neuroendocrine carcinoma of the liver: a case report.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a case of primary hepatic small cell neuroendocrine carcinoma (PHNEC). The patient was a 74-year-old male with a history of hepatitis C virus (HCV) infection, who presented with persistent right upper quadrant and lower back pain for two weeks. Imaging studies revealed multiple nodules and masses in the left hepatic lobe, accompanied by enlargement of lymph nodes at the hepatic hilum and in the retroperitoneum. Subsequent liver biopsy was performed, and to rule out potential origins from the gastrointestinal tract or lungs, gastrointestinal endoscopy and chest computed tomography (CT) scans were conducted. These evaluations confirmed the diagnosis of hepatic small cell neuroendocrine carcinoma. Following one cycle of chemotherapy combined with localized radiotherapy, a reduction in the size of both lymph nodes and hepatic lesions was observed, achieving a partial response (PR). However, follow-up imaging one month later showed significant enlargement of the hepatic masses, indicating progressive disease (PD). Subsequent chemotherapy was withheld due to progressive hepatic dysfunction and superimposed infection. The patient ultimately succumbed to multi-organ failure, with an overall survival of 4 months. The imaging features of PHNEC are nonspecific, making diagnosis relatively challenging. Improving detection rates and establishing standardized treatment guidelines remain critical challenges for clinicians. We hope this case may serve as a reference for clinicians in the field and recommend close monitoring of serological markers of liver function throughout the entire course of treatment and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.